Nanologica AB

Research Nanologica AB (NICA) on Bullrun: market cap SEK 145.65M, P/E 1.6. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is SEK 145.65M; P/E is 1.6.

Peer valuation comparison

Latest P/E is 1.58x versus a Healthcare sector median of 24.46x (93.5% below).

Latest P/E is 1.58x versus a Sweden median of 18.57x (91.5% below).

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025n/an/an/an/a-0.57SEK 3.55MSEK 21.47MSEK 22.65M
FY2024SEK 14.54M-SEK 65.63M-SEK 81.00Mn/a-1.32SEK 48.43MSEK 50.94MSEK 74.11M
FY2023SEK 1.44M-SEK 75.16M-SEK 37.60Mn/a-2.08SEK 10.05MSEK 0-SEK 1.90M
FY2022SEK 1.56M-SEK 55.23M-SEK 46.82Mn/an/aSEK 70.32MSEK 1.33MSEK 73.16M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-23SEK 145.65M1.6n/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 SEK.

About Nanologica AB

Nanologica AB (publ), a life science tools company, develops, manufactures, and sells nanoporous silica particles in China, India, Turkey, the United States, and internationally. The company offers NLAB Saga, a silica-based purification media for preparative chromatography that is developed for the purification of peptide drugs, such as insulin and GLP-1 analogues; NLAB Idun, an ion exchange product for robust, reproducible, and efficient downstream purification of GLP-1 analogues and other peptides;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Nanologica AB's market cap?

Nanologica AB's market capitalization is SEK 145.65M.

What is Nanologica AB's P/E ratio?

Nanologica AB's price-to-earnings (P/E) ratio is 1.6.

What does Nanologica AB do?

Nanologica AB (publ), a life science tools company, develops, manufactures, and sells nanoporous silica particles in China, India, Turkey, the United States, and internationally.